Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + durvalumab in metastatic pancreatic cancer with DNA damage repair alterations
2020-004859-32Phase 2Active
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Aug 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib and durvalumab in pancreatic cancer (PDAC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Overall Response Rate (ORR). Started Aug 2022; status: active.
02
Drugs
olaparibdurvalumab
03
Conditions
pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2020-004859-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004859-32.